Literature DB >> 9680919

The influence of pre-radiation salivary flow rates and radiation dose on parotid salivary gland dysfunction in patients receiving radiotherapy for head and neck cancers.

E D'Hondt1, A Eisbruch, J A Ship.   

Abstract

Radiotherapy (RT) used for head and neck cancers causes permanent salivary gland dysfunction (SGD). Previous short-term studies have demonstrated that pre-RT salivary flow rates and the amount of radiation exposure to parotid glands influence the amount of RT-induced SGD. The purpose of this study was to determine which variables are related to the development of long-term post-RT SGD. Parotid flow rates (PFR) were assessed prior to and 1 year after completion of RT in spared parotid glands from 34 patients from 2 parotid-sparing protocols. The results reveal that spared PFR were not significantly higher 1 year post-RT in patients who had high pre-RT PFR, when compared with patients with low pre-RT PFR. However, patients who received higher doses of RT to spared parotid glands had lower PFR 1 year post-RT, compared with patients who had received lower doses of RT. These one-year findings suggest that high pre-RT PFR do not provide protection against RT-induced SGD. Conversely, reduced RT dosages to contralateral parotid glands are protective of PFR after completion of RT.

Entities:  

Mesh:

Year:  1998        PMID: 9680919     DOI: 10.1111/j.1754-4505.1998.tb00913.x

Source DB:  PubMed          Journal:  Spec Care Dentist        ISSN: 0275-1879


  6 in total

1.  The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.

Authors:  Yun Li; Jeremy M G Taylor; Randall K Ten Haken; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-04       Impact factor: 7.038

Review 2.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

3.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

4.  Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics.

Authors:  Joel R Wilkie; Michelle L Mierzwa; Keith A Casper; Charles S Mayo; Matthew J Schipper; Avraham Eisbruch; Francis P Worden; Issam El Naqa; Benjamin L Viglianti; Benjamin S Rosen
Journal:  Radiother Oncol       Date:  2020-04-06       Impact factor: 6.280

5.  The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.

Authors:  T M Richards; T Hurley; L Grove; K J Harrington; G H Carpenter; G B Proctor; C M Nutting
Journal:  Oral Dis       Date:  2017-06-05       Impact factor: 3.511

6.  Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.

Authors:  A B Miah; S L Gulliford; J Morden; K L Newbold; S A Bhide; S H Zaidi; E Hall; K J Harrington; C M Nutting
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-03-17       Impact factor: 4.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.